会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • LIPOSOMAL SYSTEMS COMPRISING SPHINGOMYELIN
    • 包含SPHINGOMYELIN的脂质体系
    • WO2010041255A2
    • 2010-04-15
    • PCT/IL2009/000966
    • 2009-10-11
    • YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.BARENHOLZ, YechezkelCOHEN, Rivka
    • BARENHOLZ, YechezkelCOHEN, Rivka
    • A61K9/127A61K31/445
    • A61K9/127A61K31/445A61K31/573
    • The present disclosure provides a liposomal system comprising an aqueous medium having dispersed therein liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the aqueous medium being in iso-osmotic equilibrium with said intraliposomal aqueous compartment, the liposomes having a membrane comprising a liposome forming lipids, at least one of which being sphingomyelin (SPM), the liposomal system having increased stability as compared to the same liposomes free of SPM, and in one embodiment being stable during long-term storage, said stability being characterized in that no more than 30% of the at least one active agent is present in the aqueous medium after said storage. Further provided by the present disclosure are a method for storage of liposomes making use of the liposomal system; use of the liposomal system for the treatment of a medical condition or for the diagnostic of a medical condition; a pharmaceutical or diagnostic composition comprising the liposomal system, and a method of treating or diagnosing of a medical condition comprising administering to a subject an amount of the liposomal system.
    • 本公开提供了一种脂质体系统,其包含水分介质,其中分散有脂质体,其脂质体包封在其脂质体内水性隔室中至少一种活性剂,所述水性介质与所述脂质体内水性隔室处于等渗平衡,所述脂质体具有包含脂质体的膜 形成脂质,其中至少一种是鞘磷脂(SPM),与没有SPM的相同脂质体相比,脂质体系统具有增加的稳定性,并且在一个实施方案中在长期储存期间是稳定的,所述稳定性的特征在于不再有 在所述储存之后,至少一种活性剂的30%以上存在于水性介质中。 本公开进一步提供的是利用脂质体系统储存脂质体的方法; 使用脂质体系统治疗医疗状况或诊断医疗状况; 包含脂质体系统的药物或诊断组合物,以及治疗或诊断医学病症的方法,其包括向受试者施用一定量的脂质体系统。
    • 4. 发明申请
    • LIPOSOMAL SYSTEMS COMPRISING SPHINGOMYELIN
    • 包含SPHINGOMYELIN的脂质体系
    • WO2010041255A3
    • 2011-04-07
    • PCT/IL2009000966
    • 2009-10-11
    • YISSUM RES DEV COBARENHOLZ YECHEZKELCOHEN RIVKA
    • BARENHOLZ YECHEZKELCOHEN RIVKA
    • A61K9/127A61K31/445
    • A61K9/127A61K31/445A61K31/573
    • The present disclosure provides a liposomal system comprising an aqueous medium having dispersed therein liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the aqueous medium being in iso-osmotic equilibrium with said intraliposomal aqueous compartment, the liposomes having a membrane comprising a liposome forming lipids, at least one of which being sphingomyelin (SPM), the liposomal system having increased stability as compared to the same liposomes free of SPM, and in one embodiment being stable during long-term storage, said stability being characterized in that no more than 30% of the at least one active agent is present in the aqueous medium after said storage. Further provided by the present disclosure are a method for storage of liposomes making use of the liposomal system; use of the liposomal system for the treatment of a medical condition or for the diagnostic of a medical condition; a pharmaceutical or diagnostic composition comprising the liposomal system, and a method of treating or diagnosing of a medical condition comprising administering to a subject an amount of the liposomal system.
    • 本公开提供了一种脂质体系统,其包含水分介质,其中分散有脂质体,其脂质体包封在其脂质体内水性隔室中至少一种活性剂,所述水性介质与所述脂质体内水性隔室处于等渗平衡,所述脂质体具有包含脂质体的膜 形成脂质,其中至少一种是鞘磷脂(SPM),与没有SPM的相同脂质体相比,脂质体系统具有增加的稳定性,并且在一个实施方案中在长期储存期间是稳定的,所述稳定性的特征在于不再有 在所述储存之后,至少一种活性剂的30%以上存在于水性介质中。 本公开进一步提供的是利用脂质体系统储存脂质体的方法; 使用脂质体系统治疗医疗状况或诊断医疗状况; 包含脂质体系统的药物或诊断组合物,以及治疗或诊断医学病症的方法,其包括向受试者施用一定量的脂质体系统。
    • 5. 发明申请
    • A COMPOSITION OF MATTER COMPRISING LIPOSOMES EMBEDDED IN A POLYMERIC MATRIX AND METHODS OF USING SAME
    • 包含嵌入在聚合物基质中的脂质体的成分的组合物及其使用方法
    • WO2010041256A2
    • 2010-04-15
    • PCT/IL2009000967
    • 2009-10-11
    • YISSUM RES DEV COBARENHOLZ YECHEZKELCOHEN RIVKA
    • BARENHOLZ YECHEZKELCOHEN RIVKA
    • A61K9/127A61K9/16A61K31/445
    • A61K9/127A61K31/445A61K31/573
    • The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes. The present disclosure also provides a method of removal of non-encapsulated active agent from the composition of matter, a method of preparing said composition of matter, a pharmaceutical composition comprising said composition of matter, use of such composition of matter; a method of providing prolonged delivery of a active agent to a subject in need thereof by administering to said subject the composition of matter disclosed herein as well as a package comprising said composition of matter held within said aqueus medium and instructions for use thereof.
    • 本公开提供了一种包含在其脂质体内水性隔室中包封至少一种活性剂的脂质体的物质组合物,所述脂质体具有至少200nm的直径并且嵌入在水不溶性的吸水交联聚合物基质中。 在一个实施方案中,物质组合物保持在水性介质中,优选与脂质体的脂质体内水性隔室处于等渗平衡。 本公开还提供了从物质组合物中除去未包封的活性剂的方法,制备所述物质组合物的方法,包含所述组合物的药物组合物,所述物质组合物的使用; 通过向所述受试者施用本文公开的物质的组合物以及包含所述组合物的包装,所述组合物保持在所述aqueus培养基内以及使用说明书,提供活性剂向有需要的受试者的延长递送的方法。